About: Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $1.66 (-3.49%)
NKTX NASDAQ Nkarta Inc
Nkarta Inc share price
Atividade de preço de NKTX
Último preço
$ 1,660
Variação (24h)
-0,06 USD (3,49%)
Volume
804.99K
Volume (média 4 sem.)
-
Abertura
$ 1,74
Variação do dia
$ 1,66 - $ 1,76
Fechamento anterior
$ 1,72
Último negócio
29 Oct, 8:27 pm GMT+0
Atrasado
29 Oct, 8:27 pm GMT+0
NKTX price performance
Atrasado
29 Oct, 8:27 pm GMT+0
quote.marketSignals